Early clearance of BK polyomavirus-DNAemia among kidney transplant recipients may lead to better graft survival.
BK viremia
clearance
graft failure
outcomes
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
revised:
03
08
2024
received:
22
03
2024
accepted:
20
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
BK polyomavirus (BKPyV)-DNAemia is a common complication in kidney transplant recipients (KTRs). The significance of achieving viral clearance at different time intervals is not well understood. All adult KTRs transplanted between January 1, 2015 and December 31, 2017 who developed BKPyV-DNAemia were included. Outcomes were analyzed based on persistent clearance of BKPyV-DNAemia at 3-month intervals up to 2 years after initial detection, and for recipients with persistent BKPyV-DNAemia at last follow-up. Uncensored graft failure, death-censored graft failure (DCGF), and a composite outcome of DCGF or fall in estimated glomerular filtration rate (eGFR) by ≥50% from the time of initial BKPyV-DNAemia were outcomes of interest. Of 224 KTRs with BKPyV-DNAemia, 58 recipients (26%) achieved viral clearance by 3 months after initial detection, 105 (47%) by 6 months, 120 (54%) by 9 months, 141 (63%) by 12 months, 155 (69%) by 15 months, 167 (75%) by 18 months, 180 (80%) by 21 months, and 193 (86%) by 24 months. Nine recipients (4%) had persistent BKPyV-DNAemia at last follow-up. Compared to recipients who achieved viral clearance by 3 months, those who achieved clearance by 6 months (adjusted odds ratio [aOR]: 3.15; 95% confidence interval [CI]: 1.22-8.12; p = .02) and 9 months (aOR: 3.69; 95% CI: 1.02-13.43; p = .04) had significantly increased risk for uncensored graft failure. There was no significant association between time to viral clearance and DCGF or composite outcomes. We found a trend of increased risk for uncensored graft failure among those who cleared BKPyV-DNAemia more slowly. Aiming to clear viremia early, without risking rejection, may be beneficial for allograft function and patient morbidity and mortality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14371Informations de copyright
© 2024 The Author(s). Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Hirsch HH, Randhawa PS, Practice AIDCo. BK polyomavirus in solid organ transplantation—guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
Hassan S, Mittal C, Amer S, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of ≥4 log10/mL underestimates the diagnosis of BKV‐associated nephropathy: a single transplant center experience. Transpl Infect Dis. 2014;16(1):55‐60.
Kant S, Dasgupta A, Bagnasco S, Brennan DC. BK virus nephropathy in kidney transplantation: a state‐of‐the‐art review. Viruses. 2022;14(8):1616.
Basse G, Mengelle C, Kamar N, et al. Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. Transplant Proc. 2007;39(1):84‐87.
Cotiguala L, Masood A, Park JM, et al. Increasing net immunosuppression after BK polyoma virus infection. Transpl Infect Dis. 2021;23(2):e13472.
Hertz‐Tang AL, Astor BC, Mandelbrot DA, et al. BK viremia is not associated with adverse outcomes in the absence of BK nephropathy. Clin Transplant. 2018;32(7):e13283.
Querido S, Weigert A, Pinto I, et al. Detection of JCV or BKV viruria and viremia after kidney transplantation is not associated with unfavorable outcomes. J Med Virol. 2023;95(5):e28800.
Elfadawy N, Flechner SM, Schold JD, et al. Transient versus persistent BK viremia and long‐term outcomes after kidney and kidney‐pancreas transplantation. Clin J Am Soc Nephrol. 2014;9(3):553‐561.
Breyer I, Dodin B, Djamali A, et al. Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transpl Infect Dis. 2022;24(1):e13768.
Parajuli S, Astor BC, Kaufman D, et al. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection? Clin Transplant. 2018;32(4):e13216.
Kharel A, Djamali A, Jorgenson MR, et al. Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transpl Infect Dis. 2021;23(3):e13561.
Omić H, Kläger JP, Herkner H, et al. Clinical relevance of absolute BK polyoma viral load kinetics in patients with biopsy proven BK polyomavirus associated nephropathy. Front Med (Lausanne). 2021;8:791087.
Huang G, Wu L‐W, Yang S‐C, et al. Factors influencing graft outcomes following diagnosis of polyomavirus ‐associated nephropathy after renal transplantation. PLoS One. 2015;10(11):e0142460.
Sawinski D, Forde KA, Trofe‐Clark J, et al. Persistent BK viremia does not increase intermediate‐term graft loss but is associated with de novo donor‐specific antibodies. J Am Soc Nephrol. 2015;26(4):966‐975.
Alquadan KF, Santos AH, Leghrouz M, et al. A pilot study of immunosuppression resumption following BK viremia resolution. Transpl Infect Dis. 2021;23(2):e13508.
Stervbo U, Nienen M, Weist BJD, et al. BKV clearance time correlates with exhaustion state and T‐cell receptor repertoire shape of BKV‐specific T‐cells in renal transplant patients. Front Immunol. 2019;10:767.
Huang G, Qiu J, Yang S, et al. Factors influencing viral clearance and graft outcomes following diagnosis of polyomavirus BK‐associated nephropathy after renal transplantation. Abstract# B1042. Transplantation. 2014;98:561.
Awan AA, Niu J, Pan JS, et al. Trends in the causes of death among kidney transplant recipients in the United States (1996‐2014). Am J Nephrol. 2018;48(6):472‐481.
Ying T, Shi B, Kelly PJ, et al. Death after kidney transplantation: an analysis by era and time post‐transplant. J Am Soc Nephrol. 2020;31(12):2887‐2899.
Sim BZ, Yong KY, Slavin MA, et al. Risk factors and outcome of concurrent and sequential multiviral cytomegalovirus, Epstein‐Barr virus, BK virus, adenovirus and other viral reactivations in transplantation. Curr Opin Infect Dis. 2022;35(6):536‐544.
Herrera S, Bernal‐Maurandi J, Cofan F, et al. BK virus and cytomegalovirus coinfections in kidney transplantation and their impact on allograft loss. J Clin Med. 2021;10(17):3779
Jorgenson MR, Descourouez JL, Lyu B, et al. Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients. Clin Transplant. 2020;34(3):e13798.
Levican J, Acevedo M, León O, et al. Role of BK human polyomavirus in cancer. Infect Agent Cancer. 2018;13:12.
Cannon E, Ntala C, Joss N, et al. High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia—just a coincidence? Clin Transplant. 2023;37(12):e15113.
Jones H, Bhakta A, Jia L, et al. An unusual presentation of metastatic BK virus‐associated urothelial carcinoma arising in the allograft, persisting after transplant nephrectomy. Int J Surg Pathol. 2023;31(8):1586‐1592.
Parajuli S, Mandelbrot D. Urine CXCL10 levels as a predictor for various phases of BKPyV replication among kidney transplant recipients: utility and clinical implementation. Transplantation. 2023;107(12):2460‐2461.